#USA #San Diego #Class Action #Securities Fraud #Tempus AI

Tempus AI Investors Alert

In a crucial development for investors, Robbins Geller Rudman & Dowd LLP has announced the opportunity for those who purchased common stock of Tempus AI, Inc. (NASDAQ: TEM) to lead a class action lawsuit due to significant losses. This lawsuit pertains to shares bought between August 6, 2024, and May 27, 2025. Interested investors have until August 12, 2025, to seek appointment as lead plaintiff.

The class action lawsuit, filed under the case caption Shouse v. Tempus AI, Inc. in the Northern District of Illinois, alleges multiple serious violations of the Securities Exchange Act of 1934 by the company and its executives. It appears that Tempus AI, a company focused on advancing precision medicine through artificial intelligence, may have misled investors substantially regarding the status and operations of its business.

Allegations Against Tempus AI

The allegations surrounding Tempus AI are quite extensive. The lawsuit claims that the company inflated the true value of some contract agreements. Many of these contracts were supposedly with related parties and included dubious non-binding opt-ins. Furthermore, Tempus AI’s joint venture with SoftBank Group was under scrutiny, as it allegedly provided the appearance of 'round-tripping' capital, casting doubt on the genuine revenues reported by the company.

Additionally, the business model of Ambry Genetics Corporation, acquired by Tempus AI, is accused of relying on aggressive billing practices that could draw negative attention and prove unsustainable long-term. Significant issues arose as well when AstraZeneca scaled back its financial commitments to Tempus AI due to complicating 'pass-through payments' arranged among it, Tempus AI, and Pathos AI, Inc.

These troubling issues indicate a fundamental weakness in Tempus AI’s operations and revenue prospects, culminating in a notable decline in share price following a critical report by Spruce Point Capital Management on May 28, 2025. The publication outlined critical flags about the management and financial reporting of Tempus AI, leading to a staggering 19% drop in stock price, further alarming investors about the stability of their investments.

The Way Forward for Investors

The Private Securities Litigation Reform Act of 1995 grants investors who purchased Tempus AI shares during the designated Class Period the right to apply as lead plaintiffs in this class action lawsuit. Being appointed as a lead plaintiff is usually reserved for investors with the most substantial financial interest who can further represent the class effectively.

Potential lead plaintiffs can select any law firm to represent them in this matter. It’s important to note that participation as a lead plaintiff doesn’t determine an investor’s chances of recovering future losses, which are available to all class members regardless of their involvement in leading the case.

About Robbins Geller Rudman & Dowd LLP

Recognized as one of the premier law firms globally for representing investors affected by securities fraud, Robbins Geller has an impressive track record, having achieved over $2.5 billion in recoveries for investors last year alone. Their work encompasses significant securities class action cases, including historic recoveries.

In light of the situation, affected Tempus AI investors are urged to take prompt action. Those interested can provide their information through the specified link or contact attorneys J.C. Sanchez or Jennifer N. Caringal at Robbins Geller for consultation.

This class action lawsuit represents an opportunity for investors facing financial losses to reclaim some of their investments through collective action and legal representation.